Waldencast Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Waldencast han disminuido a una tasa media anual de -43%, mientras que en la industria Personal Products los beneficios disminuyeron en un 0.01% anualmente. Los ingresos han ido creciendo a una tasa media de 37.6% al año.
Información clave
-43.01%
Tasa de crecimiento de los beneficios
-27.86%
Tasa de crecimiento del BPA
| Crecimiento de la industria Personal Products | 20.87% |
| Tasa de crecimiento de los ingresos | 37.58% |
| Rentabilidad financiera | -49.60% |
| Margen neto | -84.44% |
| Última actualización de beneficios | 31 Dec 2025 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • May 04
WALD: Brand Strength And Injectables Launch Will Support Future Share Rebound
Analysts have trimmed their average price target on Waldencast from about $3.08 to roughly $1.87, reflecting recent EBITDA and sales shortfalls, slower growth and higher costs. At the same time, they point to ongoing brand strength and potential upside from the Saypha injectables launch.
Actualización de narrativa • Apr 20
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.
Actualización de narrativa • Apr 05
WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.Actualización de narrativa • Mar 22
WALD: Aesthetics Partnerships And Brand Strength Will Support Future Upside
Analysts have trimmed their average price target on Waldencast to $2.50, down from $4.00, reflecting recent earnings misses, ongoing investment in the Saypha injectables launch, slower-than-expected growth and higher costs tied to regulatory and review processes, even as they continue to highlight the strength of the Obagi and Milk brands. Analyst Commentary Bullish analysts are cutting their price targets on Waldencast, but several still point to what they see as underappreciated assets and future product catalysts.Actualización de narrativa • Mar 07
WALD: Jefferies Buy Rating And Aesthetics Partnerships Will Support $4 Upside
Analysts have raised their blended price target for Waldencast to $4.00, citing updated assumptions that include a lower discount rate, an adjusted profit margin outlook, and a higher future P/E multiple, as well as support from recent Street research. Analyst Commentary Street research around Waldencast has tilted constructive, with bullish analysts pointing to a clearer earnings path and a more supportive valuation framework behind the updated US$4.00 blended price target.Actualización de narrativa • Feb 21
WALD: Future Margin Recovery And Distribution Gains Will Support Share Rebound
Analysts have held Waldencast's price target at $3.00, with the latest updates reflecting lower assumed profit margins and a higher future P/E multiple, while incorporating mixed recent research that includes a Buy initiation and a prior downgrade after "disappointing" Q2 results and a reduced FY25 outlook. Analyst Commentary Recent commentary around Waldencast reflects a split view, with some focusing on long term brand potential and others zeroing in on execution hiccups and trimmed outlooks.Actualización de narrativa • Feb 06
WALD: Future Retail Distribution Gains Will Support Recovery After Earnings Setbacks
Narrative Update on Waldencast The analyst price target for Waldencast has been revised slightly lower to about $3.08 from about $3.20, as analysts balance a higher discount rate and a lower assumed future P/E with generally supportive views following the recent Jefferies initiation, along with concerns highlighted after Telsey's reaction to "disappointing" Q2 results and the reduced FY25 outlook. Analyst Commentary Recent research on Waldencast reflects a mix of optimism around the long term brand opportunity and caution around execution and near term earnings delivery.Actualización de narrativa • Jan 23
WALD: Expanded Beauty Distribution Will Support $4 Upside After Mixed Research
Analysts have trimmed their price target on Waldencast to $4.00, reflecting a slightly higher discount rate and modest adjustments to growth and P/E assumptions following mixed recent research, including a downgrade after "disappointing" Q2 results and an assumed rating elsewhere. Analyst Commentary Recent research on Waldencast sends a mixed signal, with one firm trimming its stance after Q2 and another assuming coverage with a more constructive view.Artículo de análisis • Jan 10
Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Waldencast plc ( NASDAQ:WALD ) shareholders won't be pleased to see that the share price has had a very rough month...Actualización de narrativa • Jan 07
WALD: Expanded Beauty Distribution Will Support Recovery After Recent Guidance Reset
Analysts now hold Waldencast's fair value steady at about US$4.00 per share, with a US$3.00 price target that reflects caution after what they describe as disappointing Q2 results, reduced FY25 guidance, and sales pressure at the Milk brand despite broader distribution gains. Analyst Commentary Even with the recent downgrade and cautious stance on near term execution, some commentary still points to potential upside drivers that investors are watching closely.Actualización de narrativa • Dec 14
WALD: Expanded Beauty Distribution Will Drive Rebound After Recent Earnings Reset
Analysts have trimmed their price target on Waldencast to about $4 from roughly $5, citing weaker than expected Q2 results, a lowered FY25 outlook, and slower growth at key brand Milk despite new distribution gains. Analyst Commentary Bullish analysts acknowledge that recent results and guidance have pressured near term expectations, but they continue to see upside potential for Waldencast as execution improves and the growth algorithm normalizes.Actualización de narrativa • Nov 28
WALD: Future Retail Partnerships Will Drive Recovery After Recent Setbacks
Analysts have revised Waldencast's price target downward from $3.50 to $3.20, citing weaker than expected quarterly results and ongoing challenges impacting sales growth and profitability. Analyst Commentary Bullish Takeaways Despite near-term headwinds, Waldencast continues to increase its distribution footprint.Artículo de análisis • Nov 26
Waldencast (NASDAQ:WALD) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Nov 26
Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Waldencast plc ( NASDAQ:WALD ) shares have continued their recent momentum with a 33% gain in the last month alone. Not...Seeking Alpha • Sep 23
Waldencast: Fairly Valued With Ulta Lift Already Reflected, Saypha Deal Adds Optionality
Summary Waldencast faces ongoing challenges with slowing revenue growth, heavy debt, and profitability concerns despite recent margin expansion. WALD's acquisition of Novaestiq aims to double its addressable market by entering the U.S. dermal filler space under the Obagi brand, with risk-mitigating deal terms. Recent trading updates show Milk Makeup's U.S. growth via Ulta and Amazon, while Obagi excels internationally, but overall FY 2025 guidance has been lowered. Despite a potential 20% upside to the $2.50–2.70 range, I maintain a 'Hold' rating as structural issues and dilution risks persist. Read the full article on Seeking AlphaArtículo de análisis • Aug 21
Waldencast plc (NASDAQ:WALD) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
NasdaqCM:WALD 1 Year Share Price vs Fair Value Explore Waldencast's Fair Values from the Community and select yours The...Actualización de narrativa • Aug 21
Expansion Into Ulta Beauty Stores Will Boost Future Success
The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands. Analyst Commentary Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.Artículo de análisis • May 14
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Artículo de análisis • Apr 09
It's Down 29% But Waldencast plc (NASDAQ:WALD) Could Be Riskier Than It Looks
Waldencast plc ( NASDAQ:WALD ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
Nueva narrativa • Mar 30
Expansion Into Ulta Beauty Stores Will Boost Future Success
Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.Artículo de análisis • Aug 13
Waldencast plc (NASDAQ:WALD) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 26% in the last...Seeking Alpha • Jun 28
Waldencast Plc: Investors Continue To Demand More Growth
Summary Waldencast plc provides 'Milk Makeup' & 'Obagi' brands in beauty & wellness industry. Q1 2024 saw 21% revenue growth, improved profitability trends, and increased adjusted EBITDA for Waldencast. Fiscal 2024 guidance includes expectations of continued growth through e-commerce, international sales, and brand partnerships. Read the full article on Seeking AlphaArtículo de análisis • Jun 19
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • May 11
Waldencast plc (NASDAQ:WALD) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 29% in the last...Artículo de análisis • Apr 07
Waldencast plc's (NASDAQ:WALD) Intrinsic Value Is Potentially 55% Above Its Share Price
Key Insights Waldencast's estimated fair value is US$14.29 based on 2 Stage Free Cash Flow to Equity Waldencast's...Artículo de análisis • Dec 14
Is Waldencast plc (NASDAQ:WALD) Trading At A 42% Discount?
How far off is Waldencast plc ( NASDAQ:WALD ) from its intrinsic value? Using the most recent financial data, we'll...Seeking Alpha • Aug 11
Waldencast Acquisition reports Q2 results; reaffirms FY22 guidance
Waldencast Acquisition press release (NASDAQ:WALD): Q2 Revenue of $77.1M (+23.8% Y/Y) beats by $11.6M. Pro Forma Adjusted EBITDA was $21.9M an increase of 38.6% reaching a Pro Forma Adjusted EBITDA margin of 28.4%. The company reaffirms its previously issued outlook for Fiscal 2022 provided on November 15, 2021: Net Sales of $256.3M vs. consensus of $256.00M; gross profit of $189.8M; adjusted EBITDA of $49.6M.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Waldencast. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 272 | -230 | 248 | 0 |
| 30 Sep 25 | 273 | -216 | 249 | 0 |
| 30 Jun 25 | 275 | -202 | 250 | 0 |
| 31 Mar 25 | 274 | -122 | 247 | 0 |
| 31 Dec 24 | 274 | -42 | 245 | 0 |
| 30 Sep 24 | 257 | -57 | 245 | -1 |
| 30 Jun 24 | 240 | -71 | 245 | -3 |
| 31 Mar 24 | 229 | -80 | 234 | -1 |
| 31 Dec 23 | 218 | -90 | 224 | 0 |
| 30 Sep 23 | 256 | -156 | 264 | 0 |
| 30 Jun 23 | 275 | -131 | 237 | 7 |
| 31 Mar 23 | 221 | -113 | 191 | 6 |
| 31 Dec 22 | 166 | -96 | 149 | 0 |
| 30 Sep 22 | 73 | -19 | 55 | 1 |
| 30 Jun 22 | 0 | -6 | 17 | 0 |
| 31 Mar 22 | 0 | -10 | 13 | 0 |
| 31 Dec 21 | 0 | -14 | 9 | 0 |
Ingresos de calidad: WALD actualmente no es rentable.
Margen de beneficios creciente: WALD actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: WALD no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 43% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de WALD en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: WALD no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Personal Products (-8%).
Rentabilidad financiera
Alta ROE: WALD tiene una rentabilidad financiera negativa (-49.6%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 23:54 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Waldencast plc está cubierta por 5 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Susan Anderson | Canaccord Genuity |
| Olivia Tong Cheang | Raymond James & Associates |